DelveInsight’s “Alport Syndrome Pipeline Insight 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in the Alport Syndrome pipeline landscape. It covers the Alport Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alport Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Alport Syndrome pipeline products in this space.
Explore our latest breakthroughs in Alport Syndrome Research. Learn more about our innovative pipeline today! @ Alport Syndrome Pipeline Outlook
Key Takeaways from the Alport Syndrome Pipeline Report
- In September 2025, River 3 Renal Corp. conducted a Phase 2 study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
- DelveInsight’s Alport Syndrome pipeline report depicts a robust space with 4+ active players working to develop 6+ pipeline therapies for Alport Syndrome treatment.
- The leading Alport Syndrome Companies such as Enyo Pharma, Bayer, ZyVersa Therapeutics, and others.
- Promising Alport Syndrome Therapies such as Vonafexor, Setanaxib, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan and others.
Stay informed about the cutting-edge advancements in Alport Syndrome treatments. Download for updates and be a part of the revolution @ Alport Syndrome Clinical Trials Assessment
The Alport Syndrome Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Alport Syndrome Pipeline Report also highlights the unmet needs with respect to Alport Syndrome.
Alport Syndrome Overview
Alport syndrome, a rare genetic disorder affecting around 1 in 50,000 individuals, primarily presents as microscopic hematuria and chronic kidney disease (CKD) with associated extrarenal complications. The Alport syndrome results from mutations in COL4A3, COL4A4, and COL4A5 genes, disrupting the formation of the α3–α4–α5 chain in the collagen IV network. When the disease first occurs, nonspecific symptoms such as hematuria, proteinuria, and edema appear, making it difficult to differentiate the condition from other kidney diseases, so it might be misdiagnosed.
Alport Syndrome Emerging Drugs Profile
- Vonafexor: Enyo Pharma
Vonafexor (EYP001) is a promising therapeutic candidate developed by Enyo Pharma, specifically designed to treat various kidney diseases, including Alport syndrome and chronic kidney disease (CKD). Vonafexor is a synthetic non-steroidal, non-bile acid farnesoid X receptor (FXR) agonist. It activates FXR with a high selectivity compared to other nuclear receptors and does not display any activity on bile acid receptor TGR5. This small molecule has a different structure compared to other FXR agonists and induces a differential set of target genes based on ligand binding patterns. Currently, the drug is in the Phase II stage of its development for the treatment of Alport Syndrome.
- BAY 3401016: Bayer
BAY 3401016, also known as SEMA 3A, is a monoclonal antibody developed by Bayer in collaboration with Evotec SE. It targets semaphorin 3A (SEMA3A), a protein implicated in various biological processes, including neuronal guidance and immune responses. Currently, the drug is in the Phase I stage of development to treat Alport Syndrome.
The Alport Syndrome Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Alport Syndrome with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alport Syndrome Treatment.
- Alport Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Alport Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alport Syndrome market.
Learn more about Alport Syndrome Drugs opportunities in our groundbreaking Alport Syndrome research and development projects @ Alport Syndrome Unmet Needs
Alport Syndrome Companies
Enyo Pharma, Bayer, ZyVersa Therapeutics, and others.
Alport Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Alport Syndrome Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Alport Syndrome treatment by visiting our website. Stay informed about how we’re transforming the future of Neurology @ Alport Syndrome Market Drivers and Barriers, and Future Perspectives
Scope of the Alport Syndrome Pipeline Report
- Coverage- Global
- Alport Syndrome Companies- Enyo Pharma, Bayer, ZyVersa Therapeutics, and others.
- Alport Syndrome Therapies- Vonafexor, Setanaxib, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan and others.
- Alport Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Alport Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Alport Syndrome Pipeline on our website, @ Alport Syndrome Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Alport Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Alport Syndrome– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Mid Stage Products (Phase II)
- Vonafexor: Enyo Pharma
- Early Stage Products (Phase I)
- BAY 3401016: Bayer
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Alport Syndrome Key Companies
- Alport Syndrome Key Products
- Alport Syndrome- Unmet Needs
- Alport Syndrome- Market Drivers and Barriers
- Alport Syndrome- Future Perspectives and Conclusion
- Alport Syndrome Analyst Views
- 22. Alport Syndrome
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight